New precision medicine approach could revolutionize osteoporosis care
NCT ID NCT05151484
First seen May 16, 2026 · Last updated Jun 24, 2026 · Updated 6 times
Summary
This phase 4 trial tests a personalized treatment for age-related osteoporosis using the drug teriparatide. Researchers aim to tailor therapy based on simple blood tests instead of invasive bone biopsies. The study includes 60 treatment-naive adults aged 45 and older with osteoporosis, monitoring bone density and turnover markers over one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kentucky
Lexington, Kentucky, 40536, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teriparatide (a bone-building drug given as daily injections)
What this could lead to
If successful, this could lead to a personalized, non-invasive way to treat age-related osteoporosis, reducing fractures and hospitalizations.
What could go wrong
This is a small, early-phase 4 trial with only 60 participants, so results may not apply to everyone. The treatment requires daily injections and monitoring for side effects like calcium imbalances.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.